Abstract 545P
Background
Immune checkpoint inhibitors (ICI) are standard of care in advanced non-small cell lung cancer (NSCLC) without driver mutations. A small proportion of patients (pts) treated with ICIs will achieve durable responses. We describe outcomes of a real-world cohort of pts who completed two years of pembrolizumab (pembro).
Methods
Clinical data of pts who completed 35 cycles of first-line pembro for NSCLC (or 30-34 cycles with reason for cessation other than progression) was collected retrospectively from sites across Australia via the AUstralian Registry and biObank of thoRacic cAncers (AURORA). Primary endpoints were progression rate post pembro completion and progression free survival (PFS). Local treatment of oligoprogressive disease during pembro was included. Analyses were performed using R.
Results
71 pts from six centres with a median age of 66.0 yrs, 49% male & 90% ECOG≤1 were identified. Pts were Caucasian (82%) or Asian (16%); past (69%) or current (25%) smokers with a mean 37 pack year history. Histology comprised 73% adenocarcinoma, 16% squamous. 18 pts (25%) had brain mets at diagnosis, 16 treated (8 resected, 8 RT). Median PD-L1 tumour proportion score (TPS) was 68%; 12 pts (17%) PD-L1 negative, 43 pts (61%) TPS≥50%. No pts had ALK/ROS/EGFR mutations; 29/49 tested (60%) had K-Ras mutations. Median follow up from pembro start was 38.7 months (24.5 – 65.6). Table: 545P
Total population (n=71) | |||
Pembro | 39 (55%) | Median time on pembro | 24.2 mo |
Pembro + chemo | 32 (45%) | (20.0-35.3) | |
Objective Response Rate (ORR) | 78.6% | 76.9% | |
CR | 20 (29%) | ORR pembro | 80.6% |
PR | 35 (50%) | ORR pembro+chemo | p=0.86 |
Median PFS | 46.1 mo (95%CI 39.5-NR) | PFS in PD-L1≥1%PFS in PD-L1 neg | NR (46.1-NR)28.1 mo (16.3-NR)p=0.013 |
Oligoprogression during pembro | |||
Total | 17 (24%) | ||
Locoregional | 8 | PFS oligo subgroup | 12.0 mo (9.4-18.9) |
Brain | 7 | PFS2 | 23.1 mo (20.2-NR) |
Progression post pembro | |||
Total | 20 (28%) | Median time to progression | 3.3 mo (1.0-26.3) |
Locoregional | 11 | ||
Brain | 3 | ||
Bone | 5 | ||
PD-L1≥1% | 13 | Pts with CR | 2 |
PD-L1 neg | 6 (OR 3.46, p=0.06) | Pts without CR | 18 (OR 5.06, p=0.04) |
Brain mets at diagnosis (n=18) | |||
CNS progression | 6 (33%) |
Conclusions
Pts completing two years of pembro for NSCLC in Australia had high rates of K-Ras mutation and PD-L1 expression; a significant proportion had brain metastases and treated oligoprogression. Progression rate post pembro was higher in PD-L1-negative pts and in those without complete response.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
AURORA (AUstralian Registry and biObank of thoRacic cAncers) national database. Each participating hospital in various sites throughout Australia had ethics approval to contribute to the AURORA database via their local ethics committee.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
270P - Germline BRCA1/2 pathogenic variants in Japanese patients with prostate cancer are predictive factors for androgen receptor-axis-targeted therapy or chemotherapy for castration-resistant prostate cancer
Presenter: Shigekatsu Maekawa
Session: Poster Display
Resources:
Abstract
271P - Prostate cancer with histone modifier UTX mutations can benefit from olaparib
Presenter: NOBUHITO MURAMOTO
Session: Poster Display
Resources:
Abstract
272P - Comparison between MRI-targeted and standard biopsy for prostate cancer detection: A systematic review and meta-analysis
Presenter: Andree Kurniawan
Session: Poster Display
Resources:
Abstract
273P - The diagnostic performance of cognitive MRI-targeted biopsy in biopsy-naïve patients undergoing systematic 14-region 18-core biopsy: Do the three areas affect the results?
Presenter: Yuka Toyama
Session: Poster Display
Resources:
Abstract
274P - Index tumor location influencing early biochemical recurrence after radical prostatectomy in patients with negative surgical margins
Presenter: Jun Akatsuka
Session: Poster Display
Resources:
Abstract
275P - Prognosis of metastatic castration-resistant prostate cancer in response to chemotherapy and PSMA expression in circulating tumor cells
Presenter: Naoya Nagaya
Session: Poster Display
Resources:
Abstract
276P - Prognostic significance of p53 mutation in metastatic hormone-sensitive prostate cancer
Presenter: Lakshmi Kamala
Session: Poster Display
Resources:
Abstract
277P - Vasohibin-1 expression as a biomarker of aggressive growth in prostate ductal adenocarcinoma
Presenter: Murad Salomov
Session: Poster Display
Resources:
Abstract
278P - Full-coverage radiotherapy for prostate cancer patients with oligometastases
Presenter: Bichun Xu
Session: Poster Display
Resources:
Abstract
279P - Hypofractionated radiotherapy protocol implementation and early outcomes for prostate cancer patients: A single institution retrospective review
Presenter: Thu Nguyen
Session: Poster Display
Resources:
Abstract